Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 [Yahoo! Finance]
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: Yahoo! Finance
LBS-007 is the Company's investigational medicinal product for the treatment of acute leukemia A Phase 1/2 trial in patients with relapsed or resistant acute leukemias is ongoing LBS-007, the Company's lead asset, has been granted orphan drug designations for acute myeloid leukemia and acute lymphocytic leukemia by the U.S. FDA TAIPEI CITY, Taiwan, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Lin BioScience (6696. Taiwan OTC), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting acute leukemia that have significant unmet medical needs, today announced that its lead pipeline, LBS-007, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia. Lin BioScience is currently conducting a phase 1/2 trial in patients with relapsed or resistant acute leukemias in the US, Australia, and Taiwan, and has been granted for orphan drug designation (ODD) for acute myeloid leuk
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007GlobeNewswire
- Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at Maxim Group from $60.00 to $110.00. They now have a "buy" rating on the stock.MarketBeat
- Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at HC Wainwright from $60.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswire
- Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial ResultsGlobeNewswire
BLTE
Earnings
- 11/12/24 - Beat
BLTE
Analyst Actions
- 11/15/24 - Maxim Group
BLTE
Sec Filings
- 11/20/24 - Form 144
- 11/19/24 - Form 144
- 11/12/24 - Form 6-K
- BLTE's page on the SEC website